[4]. NCCN Guidelines Version 2.2025 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [5]. Sharman JP, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus ob...
[9]Roeker LE, DerSarkissian M, Ryan K, et al. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv. 2023;7(16):4291-4301. [10]Margaret Krackeler, et al. Real-world...
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are commercially available, and, in many cases, a lack of randomized ...
chemoimmunotherapy, and targeted therapy1,2,3,4. According to the international workshop on CLL guidelines, CLL treatment is not recommended unless cytopenia, symptomatic disease, or short lymphocyte doubling time is present;5most
[5]Hallek M, Cheson BD, Catovsky D,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348. ...
Males with female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose. are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA® and for 1 week...
Treatment recommendations for patients with del (17p) Although these patients have a poor prognosis and there is no clear standard of care, the National Comprehensive Cancer Network (NCCN) guidelines list the following as preferred regimens for first-line treatment[12]: ...
COPIKTRA (duvelisib) is an oral treatment for chronic lymphocytic leukemia or small lymphocytic leukemia (CLL or SLL). See Full Prescribing Information including BOXED WARNING. Copiktra is indicated for the treatment of adult patients with relapsed or re
Panelists discuss how treatment sequencing in chronic lymphocytic leukemia (CLL) should be personalized based on prior therapy responses and resistance patterns, with emerging real-world data from ASH 2024 informing decisions about re-treatment with drug classes and treatment holi...
EP: 8.Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies EP: 9.Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy EP: 10.Relapse After Venetoclax-Based Therapy: Early vs Late Management EP: 11.Progression on BTK I...